(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

KRAZATI

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: United States

Quick snapshot

KRAZATI

ST13

US500000090603915

Class

5, 42

Filing

90603915

Registration

7019779

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

37

Latest update

06/25/2024

Trademark type

Word

Nice classes

5, 42

Filing date

03/25/2021

Registration date

04/04/2023

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

04/04/2023

Last transaction

06/25/2024

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Filing basis

Intent to use

First use anywhere

12/13/2022

First use in commerce

12/13/2022

Drawing code

4

Owner type

03

Owner location

San Diego, CA, US

Examiner

HSU, FONG

Law office

O20

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Mirati Therapeutics, Inc.

Representatives

Marilyn F. Kelly Bristol-Myers Squibb Company

Technical classification

Nice Classes

Class 5Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of lung cancer; pharmaceutical preparations for the treatment of non-small cell lung carcinoma; pharmaceutical preparations for the treatment of colorectal carcinoma; pharmaceutical preparations for the treatment of pancreatic cancer; pharmaceuticals comprising small molecules for the treatment of cancer; pharmaceuticals comprising small molecules for the treatment of infectious diseases; pharmaceuticals comprising small molecules for the treatment of lung cancer; pharmaceuticals comprising small molecules for the treatment of non-small cell lung carcinoma; pharmaceuticals comprising small molecules for the treatment of colorectal carcinoma; pharmaceuticals comprising small molecules for the treatment of pancreatic cancer; pharmaceuticals comprising compounds for the treatment of cancer; pharmaceuticals comprising inhibitors for the treatment of cancer; pharmaceuticals for the treatment of solid tumors; pharmaceuticals for the treatment of advanced solid tumors

Class 42

research and development of pharmaceuticals in the field of oncology; providing information in the field of scientific and medical research related to oncology; research and development of pharmaceuticals; providing information in the field of scientific and medical research related to pharmaceuticals

Publications

History of USPTO decisions and trademark events.

37 publications found

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

06/25/2024

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

06/25/2024

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

06/25/2024

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

04/04/2023

R.PR

REGISTERED-PRINCIPAL REGISTER

04/04/2023

SUNA

NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED

02/28/2023

CNPR

ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

02/27/2023

SUPC

STATEMENT OF USE PROCESSING COMPLETE

02/01/2023

AITU

CASE ASSIGNED TO INTENT TO USE PARALEGAL

01/30/2023

IUAF

USE AMENDMENT FILED

01/02/2023

EISU

TEAS STATEMENT OF USE RECEIVED

01/02/2023

EXRA

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

10/19/2022

EX1G

SOU EXTENSION 1 GRANTED

10/17/2022

EXT1

SOU EXTENSION 1 FILED

10/17/2022

EEXT

SOU TEAS EXTENSION RECEIVED

10/17/2022

NOAM

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

04/19/2022

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

02/22/2022

PUBO

PUBLISHED FOR OPPOSITION

02/22/2022

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

02/02/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

01/18/2022

XAEC

EXAMINER'S AMENDMENT ENTERED

01/15/2022

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

01/15/2022

GNEA

EXAMINERS AMENDMENT E-MAILED

01/15/2022

CNEA

EXAMINERS AMENDMENT -WRITTEN

01/15/2022

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

12/20/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

12/20/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

12/20/2021

ALIE

ASSIGNED TO LIE

11/09/2021

GNRN

NOTIFICATION OF NON-FINAL ACTION E-MAILED

11/08/2021

GNRT

NON-FINAL ACTION E-MAILED

11/08/2021

CNRT

NON-FINAL ACTION WRITTEN

11/08/2021

DOCK

ASSIGNED TO EXAMINER

11/01/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

07/01/2021

CHAN

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED

06/30/2021

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

06/30/2021

COAR

TEAS CHANGE OF OWNER ADDRESS RECEIVED

06/30/2021

NWAP

NEW APPLICATION ENTERED

03/29/2021

Continuous trademark protection

Get notified about every new filing that threatens KRAZATI or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.